Loading...
XNAS
LMAT
Market cap2.33bUSD
Jul 09, Last price  
102.40USD
1D
0.57%
1Q
-10.66%
Jan 2017
304.10%
IPO
1,487.60%
Name

LeMaitre Vascular Inc

Chart & Performance

D1W1MN
XNAS:LMAT chart
P/E
40.53
P/S
9.37
EPS
2.53
Div Yield, %
0.79%
Shrs. gr., 5y
2.29%
Rev. gr., 5y
14.05%
Revenues
250m
+13.53%
34,628,00041,446,00048,720,00050,908,00056,060,00057,685,00056,735,00064,549,00071,097,00078,352,00089,151,000100,867,000105,568,000117,232,000129,366,000154,424,000161,651,000193,484,000219,863,000249,602,000
Net income
58m
+31.10%
-1,172,000-2,934,000-3,314,0001,598,0006,013,0002,143,0002,571,0003,202,0003,915,0007,758,00010,590,00017,177,00022,943,00017,934,00021,220,00026,907,00020,636,00030,105,00044,038,00057,734,000
CFO
81m
+84.14%
-526,000-1,826,000581,0005,440,0007,052,0003,170,0004,722,0005,388,0005,512,00011,438,00016,896,00022,868,00019,506,00014,179,00034,800,00035,102,00025,378,00036,751,00044,124,00081,251,000
Dividend
Nov 20, 20250.2 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Operating worldwide, LeMaitre Vascular, Inc. specializes in the development, distribution, and maintenance of medical devices and implants for treating peripheral vascular disease. Its product portfolio encompasses a range of catheters, including angioscopes, which are fiberoptic tools for internal blood vessel visualization; embolectomy catheters for removing blood clots from arteries or veins; occlusion catheters that temporarily halt blood flow; perfusion catheters for infusing blood and other fluids into the vasculature; and thrombectomy catheters, featuring a silicone balloon for extracting venous thrombi. The company also furnishes carotid shunts, designed to temporarily redirect blood flow to the brain during carotid endarterectomy surgery to clear arterial plaque. Another offering is radiopaque tape, a medical-grade adhesive applied externally to help interventionists precisely cross-reference skin locations with underlying anatomical features like vessels or lesions. Further products include valvulotomes, instruments used to cut or disrupt valves within the saphenous vein, enabling it to function as an arterial bypass to carry blood past diseased arteries to the lower leg or foot. Additionally, LeMaitre supplies vascular grafts for bypassing or replacing compromised arteries. Moreover, the company provides vascular and cardiac patches for post-surgical vessel closure. Its closure systems employ titanium clips for connecting vessels, offering an alternative to traditional sutures. Products are distributed via both its direct sales force and a network of distributors. Founded in 1983 as Vascutech, Inc., the company rebranded as LeMaitre Vascular, Inc. in April 2001. It is headquartered in Burlington, Massachusetts.
IPO date
Oct 19, 2006
Employees
591
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT